CELU Celularity Inc - Ordinary Shares - Class A

$CELU Q2 '26 Earnings Results & Recap Celularity reported Q2 2026 revenue of $5.43M, down from $5.74M; product sales were $4.06M, and net income was $706M versus a -$24.52M loss.

$CELU is quietly building a contract-manufacturing hub around Florham Park. In two months it has signed two new programs, and they look connected. In August, Celularity agreed to manufacture Dezawa MuseCells, MuseExosomes, and MuseSecretome for MuseCell Innovations, which has floated a non-binding estimate of more than $300M in purchases over five years. On October 29, it added an exclusive US finish-manufacturing deal with Vesalius for Peptual peptide APIs. Vesalius says it has financial ties to MuseCell, so Celularity could be becoming the US production partner for a growing regenerative-longevity network. The $13.3M NexGel deal shed non-core biomaterials and retired about $13M of debt. Fresh financing, regained Nasdaq compliance, and a purpose-built cGMP facility finally have a pipeline of third-party work to fill it. If the FDA opens the peptide compounding list and MuseCell programs scale, this could turn from a story into revenue. 🚀

$CELU Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States https://www.businesswire.com/news/home/20261029804397/en/Celularity-and-Vesalius-Longevity-Labs-Sign-Exclusive-Collaboration-for-Peptual-Peptide-APIs-Manufactured-in-the-United-States

$CELU Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

$CELU I’m cautiously bullish. But there’s concerns with this company that I have real concerns about. Barachs involvement brings me a bit of peace of mind. But real other issues still exist. Looks at this premarket spread. The last few PM PRs have come out at 915. Here’s to hoping

$CELU I’m going bullish on today. Today’s a big day. Those who know, know. I’m hopeful for premarket. After hours is possible as well though.

$CELU is trading sharply higher on partnership following a Business Wire release. Celularity and Vesalius Longevity Labs signed an exclusive manufacturing agreement for Peptual peptide APIs at Celularity's New Jersey facility. RTPR pushed this release out to users at 9:00:00 AM ET

$CELU horrible earnings again. Showing positive 2 cents not from revenue but from a SLS settlement which is a one time thing. Only 500k cash, massive expenses. I don’t understand this company. They will be diluting for sure. Which means under $1 again soon